Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jerry Olson who wrote (88472)	3/14/2000 9:27:00 PM
From: nokomis	Read Replies (1) \| Respond to of 120523

Jerry,..and here I had ONLY 58 sell for WAVX...amazing link and thank you!!! marketwatch.newsalert.com

To: Jerry Olson who wrote (88472)	3/15/2000 3:46:00 AM
From: Adelle	Respond to of 120523

biz.yahoo.com Basically the only thing of concern is this section of the latest Reuters news: ---------------- Talks between Celera and the researchers appeared to fall apart last week over Celera's demands to retain exclusive commercial rights of distribution of any merged products. Paul Gilman, a senior Celera executive, said his company will have spent $200 million to sequence the human genome by the end of the year, by which time the job will be finished. He said Celera was willing to share its data with U.S. researchers, but only if the combined data was kept off-limits to Incyte and other Celera commercial rivals. ``Incyte has told its customers they need not subscribe to Celera's database because Incyte intends to copy our data and sell it to their own subscribers,' Gilman told Reuters. Incyte president Randy Scott denied the allegation. ``We have no interest in accessing Celera's data. We're simply telling our subscribers that the (U.S.) Human Genome Project is already providing data for free and we'll continue to pass it along to our clients.'